Recombinant SARS-CoV-2 Spike RBD(L452R, T478K) protein (Myc Tag, His Tag)
种属
SARS-CoV-2
纯度
>95 %, SDS-PAGE
标签
Myc Tag, His Tag
生物活性
EC50: 30-130 ng/mL
验证数据展示
产品信息
| 纯度 | >95 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 |
Immobilized SARS-CoV-2 Spike RBD (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human ACE2 (hFc tag) with a linear range of 30-130 ng/mL. |
| 来源 | HEK293-derived SARS-CoV-2 Spike RBD protein Arg319-Phe541 (Accession# YP_009724390.1, L452R, T478K) with a Myc tag and a His tag at the C-terminus. |
| 基因ID | 43740568 |
| 蛋白编号 | YP_009724390.1 |
| 预测分子量 | 27.7 kDa |
| SDS-PAGE | 35-45 kDa, reducing (R) conditions |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
SARS-CoV-2 belongs to the beta-coronavirus genus in the family Coronaviridae, which includes four structural proteins: spike protein (S), membrane protein (M), pericapsid protein (E), and nucleocapsid protein (N). Among the four structural proteins of the SARS-CoV-2, the S and the N are the main immunogens. The S protein of SARS-CoV-2 is the molecular determinant of viral attachment, fusion, and entry into host cells. The S protein comprises an N-terminal S1 subunit responsible for binding the virus to the receptor and an S2 C-terminal subunit responsible for the fusion of the virus with the cell membrane. S1 is further divided into an N-terminal domain (NTD) and a receptor-binding domain (RBD). The RBD domain of S1 tightly binds to the peptidase domain of ACE2, playing key roles in determining host range, tropism, and infectivity. The coronavirus RBD is the main target of neutralizing antibodies and has been a focus of vaccine design and therapeutic efforts.
参考文献:
1. Lo Sasso B. et al. (2021). Diagnostics (Basel). 11:1135. 2. Zost SJ. et al. (2020). Nature. 584:443-449. 3. Li K. et al. (2020). Nat Commun. 11:6044. 4. Ahmad I. et al. (2021). Top Curr Chem (Cham). 379:40. 5. Jia L. et al. (2020). MedComm. 2:442-452.
